Table 1.
Patients’ characteristics
| All patients | Treatmenta | No treatment | |
|---|---|---|---|
| N (%) | 111 | 72 (65) | 39 (35) |
| Female gender, n (%) | 54 (49) | 36 (50) | 18 (46) |
| Age (years), median (range) | 62 (32–79) | 59 (32–78) | 66 (44–79) |
| Tumor site, n (%) | |||
| Stomach | 38 (34) | 31 (43) | 7 (18) |
| Colon/rectum | 21 (19) | 15 (21) | 6 (15) |
| Pancreas/biliary system | 20 (18) | 13 (18) | 7 (18) |
| Esophagus | 10 (9) | 4 (6) | 6 (15) |
| Lung | 10 (9) | 3 (4) | 7 (18) |
| Ovary | 2 (2) | 1 (1) | 1 (3) |
| Others | 10 (9) | 5 (7) | 5 (13) |
| Stage, n (%) | |||
| III | 25 (23) | 15 (21) | 10 (26) |
| IV | 86 (77) | 57 (79) | 29 (74) |
| Metastasis, n (%) | 73 (68) | 48 (67) | 25 (64) |
| Karnofsky PS, median (range) | 70 (60–80) | 70 (60–80) | 70 (60–80) |
| BMI, median (range) | 20.7 (13.5–29.5) | 21.2 (13.5–29.5) | 19.7 (13.5–28.7) |
| Weight lossb, (%), median (range) | 11.7 (0–38.3) | 10.6 (2.1–38.3) | 12.3 (0–31.7) |
| PG‐SGA category, n (%) | |||
| B | 41 (37) | 29 (40) | 12 (31) |
| C | 70 (63) | 43 (60) | 27 (69) |
| Oral food intake (Kcal), median (range) | 500 (200–1300) | 500 (200–1250) | 550 (200–1300) |
| Indication for HPN, n (%) | |||
| Intestinal sub(obstruction)c | 90 (81) | 59 (82) | 31 (80) |
| SBS; high‐output ileostomy or fistula | 14 (13) | 8 (11) | 6 (15) |
| EN not tolerated or feasible | 7 (6) | 5 (7) | 2 (5) |
| HPN duration (days), median (range) | 137 (21–576) | 139 (27–576) | 86 (21–317) |
PS, performance status; BMI, body mass index; PG‐SGA, patient‐generated subjective global assessment; SBS, short bowel syndrome; EN, enteral nutrition; HPN, home parenteral nutrition.
a
Treatment: chemotherapy and/or radiation therapy.
b
In the last 3 months before HPN.
c
Intra‐abdominal recurrence and/or peritoneal carcinomatosis.